Blood endocan as a biomarker for breast cancer recurrence
Cancer Biomarkers · 2024
DOI: 10.3233/cbm-240034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biomarkers, 2024. Verfasst von Kentaro Daiki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Bioanalysis and Onco-Pharmaceutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, Proteoglycans, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Endocan was reported to affect breast cancer patients negatively and was able to be detected from patients’ blood. OBJECTIVE: This study aimed to investigate if the measurement of blood endocan in breast cancer patients with high ESM1 expression could be an effective tool to detect postoperative recurrence compared with existing tumor markers. METHODS: Blood was collected before and after the tumor resection from the mouse models of breast cancer, and endocan levels were measured while visualizing metastatic recurrence with noninvasive luminescence imaging. In clinical settings, blood was withdrawn from 16 breast cancer patients before and after the tumor resection, and the effect of lumpectomy on blood endocan level was evaluated. Additionally, the blood endocan from 20 patients diagnosed with postoperative recurrence was measured, and their positivity rate for endocan was compared with that for serum carcinoembryonic antigen (CEA) or cancer antigen 15-3 (CA15-3). RESULTS: Our preclinical and clinical experiments revealed that blood endocan levels reflected tumor burden. Furthermore, over 60% of patients suffering from postoperative recurrence who tested negative for CEA or CA15-3 were positive for endocan. CONCLUSIONS: Our results support the clinical significance of endocan in breast cancer patients for detecting breast cancer recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Bioanalysis and Onco-Pharmaceutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
- Department of Breast Surgical Oncology, Tokyo Rosai Hospital, Tokyo, Japan.
- Department of Breast Surgical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan.
- Institute for Clinical Genetics and Genomics, Showa University, Tokyo, Japan.
- Laboratory of Biofunctional Science, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
- Department of Pathology, Showa University School of Medicine, Tokyo, Japan.
Zitieren
APA
Daiki, K., Kanada, Y., Nagata, A., Taruno, K., Igarashi, K., Yamochi, T., Ota, H., Sato, F., Nakamura, S., & Kato, Y. (2024). Blood endocan as a biomarker for breast cancer recurrence. Cancer Biomarkers. https://doi.org/10.3233/cbm-240034
Vancouver
Daiki K, Kanada Y, Nagata A, Taruno K, Igarashi K, Yamochi T, et al. Blood endocan as a biomarker for breast cancer recurrence. Cancer Biomarkers. 2024. doi:10.3233/cbm-240034
BibTeX
@article{Daiki2024,
author = {Daiki, Kentaro and Kanada, Yoko and Nagata, Aya and Taruno, Kanae and Igarashi, Katsuhide and Yamochi, Toshiko and Ota, Hirotaka and Sato, Fumiaki and Nakamura, Seigo and Kato, Yoshinori},
title = {Blood endocan as a biomarker for breast cancer recurrence},
journal = {Cancer Biomarkers},
year = {2024},
doi = {10.3233/cbm-240034}
}
EUVIMED